Abstract
Interventional radiology has long been contributing to the treatment of oncology patients by means of diagnostic procedures such as fine-needle aspiration or core biopsy under imaging guidance. IR techniques are worldwide used for palliative treatment: venous, biliary, esophageal, duodenal, enteric, ureteric, or airway obstructions due to malignant compression or infiltration are now being treated almost exclusively by percutaneous or transoral stent insertion. Percutaneous image-guided drainage, embolization, and stenting play a prominent role in management of complications of the initial disease or initial treatment. Vertebroplasty and cementoplasty are the current practice in management of certain bone metastases. Moreover, invention and development of medical devices led to a breakthrough of interventional radiology to potentially curative procedures. Transarterial chemoembolization and thermal tumor ablation are listed among the curative options for certain cancer patients; hence, they occupy the major part of this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Uberoi R, Morgan R (2006) CIRSE quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Interv Radiol 29:319–322
Rosenthal DI, Hornicek FJ, Wolfe MW et al (1998) Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment. J Bone Joint Surg Am 80(6):815–821
Brace CL (2009) Radiofrequency and microwave ablation of the liver, lung, kidney and bone: what are the differences. Curr Probl Diagn Radiol 38:135–143
Simon CJ, Dupuy DE, Mayo-Smith WN (2005) Microwave ablation: principles and applications. Radiographics 25:S69–S83
Livraghi T, Meloni F, Solbiati L et al (2012) Complications of microwave ablation for liver tumors: results of a multicenter study. Cardiovasc Intervent Radiol 35:868–874
Kojima Y, Suzuki S, Sakaguchi T et al (2000) Portal vein thrombosis caused by microwave coagulation therapy for hepatocellular carcinoma: report of a case. Surg Today 30:844–848
Kunkle DA, Uzzo RG (2008) Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 113:2671–2680
Yang Y, Wang C, Lu Y et al (2012) Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 19(6):674–684. Accessed 24 May 2011
Smith MT, Ray CE (2006) The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy. Semin Interv Radiol 23:39–45
Seifert JK, Morris DL (1999) World survey on the complications of hepatic and prostate cryotherapy. World J Surg 23:109–113
Llovet JM, Di Biseglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:678–711
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma: conclusions of the barcelona 2000 EASL conference. J Hepatol 35:421–430
Tateishi R, Shiina S, Teratami T et al (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 103:1201–1209
Tanabe KK, Curley SA, Dodd GD et al (2004) Radiofrequency ablation: the experts weigh in. Cancer 100:641
Kagawa T, Koizumi J, Koijima S et al (2010) Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 116:3638–3644
Rossi S, Garbagnati F, Lencioni R et al (2000) Percutaneous radiofrequency thermal ablation of non resectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217:119–126
Ohmoto K, Yoshioku N, Tomiyama Y et al (2007) Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinoma: a retrospective comparative study. Hepatogastroenterology 54:985–989
Akahane M, Koga H, Kato N et al (2005) Complications of percutaneous radiofrequency ablation for hepatocellular carcinoma: imaging spectrum and management. Radiographics 25:S57–S68
Sato M, Tateishi R, Yasunaga H et al (2012) Mortality and morbidity of hepatectomy, radiofrequency ablation and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 47:1125–1133
Howenstein MJ, Sato KT (2010) Complication of radiofrequency ablation of hepatic, pulmonary and renal neoplasms. Semin Interv Radiol 27:285–295
Frich L, Halvarsen PS, Skulstad H et al (2007) Microbubbles in the pulmonary artery generated during experimental hepatic radiofrequency ablation is correlated with increased pulmonary arterial pressure. J Vasc Interv Radiol 18:437–442
Wah TZ, Arellano RS, Gervais DA et al (2005) Image-guided percutaneous radiofrequency ablation and incidence of post-radiofrequency ablation syndrome: prospective survey. Radiology 237:1097–1102
Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508
Munireddy S, Katz S, Somasundar P et al (2012) Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J Gastrointest Oncol 3:69–77
Govaert KM, van Kessel CS, Lolkema M et al (2012) Does radiofrequency ablation add to chemotherapy for unresectable liver metastasis? Curr Colorectal Cancer Rep 8:130–137
Ruers T, Punt CJ, van Coevorden F et al (2010) Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRLM). J Clin Oncol 28(15 suppl):abstract 3526
Weng M, Zhang Y, Zhou D et al (2012) Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS One 7:e45493
Donado M, Ribero D, Morris-Stiff G et al (2007) New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 1:20–27
Shibata T, Yamamoto Y, Yamamoto N et al (2003) Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 14:1535–1542
Sipperstein AE, Berber E, Ballem N et al (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10 year experience. Ann Surg 246:559–565
Abdalla EK, Vauthey JN, Ellis JM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825
Bleicher RJ, Allegra DP, Nora DT et al (2003) Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 10:52–58
Yangkui Gu, Zhimei Huang, Haifeng Gu, Fei Gao, Tianqi Zhang, Senmiao Huang, Jinhua Huang, (2018) Does the Site of the Primary Affect Outcomes When Ablating Colorectal Liver Metastases with Radiofrequency Ablation?. CardioVascular and Interventional Radiology 41 (6):912–919
Hellman P, Ladjevardi S, Kogseid B et al (2002) Radiofrequency tissue ablation using cooltip for liver metastases of endocrine tumors. World J Surg 26:1052–1056
Berber E, Flesher N, Sipperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26:985–990
Massaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-years experience evaluating predictors of survival. Surgery 142:10–19
Gc H, Tunkali K, Tatli S et al (2008) Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol 19:1311
Dupuy DE, DiPetrillo T, Gandhi S et al (2006) Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest 129:738–745
Pereira PL, Massala S (2012) Standards of practice: guidelines for thermal ablation of primary and secondary lung tumors. Cardiovasc Intervent Radiol 35:247–254
De Baere T (2011) Lung tumor radiofrequency ablation: where do we stand? Cardiovasc Intervent Radiol 34:241–251
De Baere T, Palussiere J, Auperin A et al (2006) Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 240:587–596
Yoshimatsu R, Yamagami T, Terayama K et al (2009) Delayed and recurrent pneumothorax after radiofrequency ablation of lung tumors. Chest 135:1002–1009
Sakurai J, Mimura H, Gobara H et al (2010) Pulmonary artery pseudoaneurysm related to radiofrequency ablation of lung tumor. Cardiovasc Intervent Radiol 33:413–416
Pennathur A, Luketich JD, Abbas G et al (2007) Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg 134:857–864
Kodama H, Yamakado K, Takaki H et al (2012) Lung radiofrequency ablation for the treatment of unresectable recurrent non-small cell lung cancer after surgical intervention. Cardiovasc Intervent Radiol 35:563–569
Simon CJ, Dupuy DE, DiPetrillo TA et al (2007) Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 243:268–275
Gillams A, Khan Z, Osborn P et al (2013) Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Intervent Radiol 36(3):724–730
Davalos RV, Mir LM, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:223–231
Wendler JJ, Porch M, Hühne S et al (2013) Short and mid-term effects of irreversible electroporation on normal renal tissue: an animal model. Cardiovasc Intervent Radiol 36(2):512–520
Wendler JJ, Pech M, Blaschke S et al (2012) Angiography in the isolated perfused kidney: radiological evaluation of vascular protection in tissue ablation by irreversible electroporation. Cardiovasc Intervent Radiol 35:383–390
Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103(4):914–921
Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–590
Nakamura H, Hashimoto T, Oi H et al (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–786
Nakajo M, Kobayashi H, Shimabukuro K et al (1988) Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 29:1066–1077
Kan Z, Sato M, Ivancev K et al (1993) Distribution and effect of iodized poppy seed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology 186:261–266
Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Bead Block for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33(3):541–551
Nicolini A, Martinetti L, Crespi S et al (2010) Transarterial chemoembolization with epirubicineluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21(3):327–332
Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481
Lee KH, Liapi EA, Cornell C et al (2010) Doxorubicin-loaded Quadrasphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 33(3):576–582
Gupta S, Wright KC, Ensor J et al (2011) Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. Cardiovasc Intervent Radiol 34(5):1021–1030
Malagari K, Pomoni M, Spyridopoulos TN et al (2011) Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 34(4):774–785
Brown DB, Cardella JF, Sacks D et al (2006) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 17(2 Pt 1):225–232
Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171
Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30(1):6–25
Malagari K, Pomoni M, Moschouris H et al (2012) Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 35(5):1119–1128
Burrel M, Reig M, Forner A et al (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 56(6):1330–1335
Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterialinfusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenoustherapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395
Martin RC II, Scoggins CR, Tomalty D et al (2012) Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 16(8):1531–1538
Stuart K (2003) Chemoembolization in the management of liver tumors. Oncologist 8:425–437
Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361
Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783. (discussion 83–85)
Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590–1602
Roche A, Girish BV, de Baère T et al (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13(1):136–140
Stokes KR, Stuart K, Clouse ME (1993) Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 4(3):341–345
Memon K, Lewandowski RJ, Mulcahy MF et al (2012) Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 83(3):887–894
Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64
Kennedy AS, Coldwell D, Nutting C et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425
Kooby DA, Egnatashvili V, Srinivasan S et al (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolisation for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21(2):224–230
Carr BI, Kondragunta V, Buch SC et al (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116(5):1305–1314
Lewandowski RJ, Kulik LM, Riaz A et al (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920–1928
Katsanos K, Sabharwal T, Adam A (2010) Stenting of the upper gastrointestinal tract: current status. Cardiovasc Intervent Radiol 33:690–705
Adam A, Morgan R, Ellul J et al (1996) A new design of the esophageal wallstent endoprosthesis resistant to distal migration. Am J Roentgenol 170:1477–1482
Sabharwal T, Hamady MJ, Chui S et al (2003) A randomized prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third esophageal carcinoma. Gut 52:922–926
Sabharwal T, Morale JP, Irani FG et al (2005) Quality improvement guidelines for placement of esophageal stents. Cardiovasc Intervent Radiol 28:284–288
Farrugia M, Morgan RA, Latham JA et al (1997) Perforation of the esophagus secondary to insertion of covered wallstent endoprostheses. Cardiovasc Intervent Radiol 20:428–430
Katsanos K, Sabharwal T, Adam A (2011) Stenting of the lower gastrointestinal tract: current status. Cardiovasc Intervent Radiol 34:462–473
Baerlocher MO, Asch MR, Dixon P et al (2008) Interdisciplinary Canadian guidelines on the use of metal stents in the gastrointestinal tract for oncological indications. Can Assoc Radiol J 59:107–122
Adam A, Watkinson A (1996) Interventional radiology-a practical guide. Radcliffe Medical Press, Oxford
Lammer J, Hausegger KA, Fluckiger F et al (1996) Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology 201:167–172
Kaskarelis IS, Papadaki MG, Papageorgiou GN et al (1999) Long-term follow-up in patients with malignant biliary obstruction after percutaneous placement of uncovered wallstent endoprosthesis. Acta Radiol 40:528–533
Brountzos EN, Ptochis N, Panagiotou I et al (2006) A survival analysis of patients with malignant biliary strictures treated by percutaneous metallic stenting. Cardiovasc Intervent Radiol 30:66–73
Krokidis M, Fanelli F, Orgera G et al (2011) Percutaneous palliation of pancreatic head cancer: comparison of ePTFE/FEP-covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol 34:352–361
Uthappa MC, Kellett MJ (2004) Interventional radiology in malignant urinary tract obstruction. In: Adam A, Dondelinger R, Mueller PR (eds) Interventional radiology in cancer. Springer, Berlin
Dyer RB, Regan JD, Kavanagh PV et al (2002) Percutaneous nephrostomy with extension of the technique: step by step. Radiographics 22:503–525
Silverman SG, Deuson TE, Kane N et al (1998) Percutaneous abdominal biopsy: cost-identification analysis. Radiology 206(2):429–435
Smith EH (1991) Complications of percutaneous abdominal fine-needle biopsy. Radiology 178(1):253–258
Cham MD, Lane ME, Henschke CI et al (2008) Lung biopsy: special techniques. Semin Respir Crit Care Med 29(4):335–349
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Glynos, M.K., Malagari, K.S. (2018). Interventional Radiology in Oncology. In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-68873-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-68873-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68872-5
Online ISBN: 978-3-319-68873-2
eBook Packages: MedicineMedicine (R0)